Findings of a new study led by MACABI healthcare in collaboration with researchers from the Faculty of Biology

24 August 2021

According to a new Israeli study conducted by Maccabi Health Services in collaboration with researchers from the Faculty of Biology at the Technion, the COVID-19 vaccine is 91% effective in preventing infection 2 weeks after the second dose

“According to the study, the Pfizer vaccine’s efficacy starts increasing 12 days after the first dose, reaching a peak of 91.2% in preventing infection and 99.3% in preventing symptomatic disease. The vaccine is found to be slightly less effective in elderly patients and patients with diabetes.”

The study was conducted by Kahn Sagol Maccabi Research and Innovation Center (KSM) led by Dr. Tal Patalon, in collaboration with Prof. Roy Kishony and Dr. Idan Yelin pf the Faculty of Biology and The Interdisciplinary Center for Life Sciences & Engineering at the Technion.

To read the full article in Haaretz (in Hebrew):

https://www.haaretz.co.il/health/corona/.premium-1.9642969

 

Also available to you on social media
Font Resize
Contrast